Today

Agents

Chat

Arena

Discover

More

App

Brief-TScan Therapeutics Q2 Net Income USD -30.359 Million - TCRX News | Rallies

Brief-TScan Therapeutics Q2 Net Income USD -30.359 Million

TCRX•2026-08-12

TScan Therapeutics reports second-quarter results

Aug. 12 (Reuters) - TScan Therapeutics Q2 income from operations USD -30.493 million.

Q2 operating expenses USD 31.544 million
Q2 collaboration and license revenue USD 1.051 million
Q2 basic EPS USD -0.23

Related News

TScan Therapeutics Q2 net loss narrows on lower R&D costs

TCRX•2026-08-12

Camden Property Trust <CPT.N>: Morgan Stanley cuts target price to $118.00 from $120.00

CPT•2026-08-12

Altimmune Q2 FY26 net loss narrows to $22.8 million; cash and investments climb to $519 million

ALT

•

2026-08-12

Madison Square Garden Entertainment Q4 Revenue USD 196.3 Million Vs. IBES Estimate USD 166.6 Million

MSGE•2026-08-12

LeonaBio targets Phase 3 ELAINE-3 enrollment completion in Q4 2026, topline data seen in H2 2027

LONA•2026-08-12